L3VLUP
ProSign in

ALKS · JNJ in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

ALKSJNJ
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • ALKS
  • JNJ
0204060202120222023202420252026
Holders and value by quarter
QuarterALKSJNJ
Q3 202010 holders, $1.0bn30 holders, $26.2bn
Q4 202013 holders, $1.2bn32 holders, $26.6bn
Q1 202112 holders, $1.1bn31 holders, $25.3bn
Q2 202113 holders, $1.3bn37 holders, $25.6bn
Q3 202111 holders, $1.4bn40 holders, $24.1bn
Q4 20219 holders, $1.1bn33 holders, $25.2bn
Q1 202210 holders, $1.2bn35 holders, $28.2bn
Q2 202212 holders, $903m33 holders, $26.9bn
Q3 202210 holders, $547m36 holders, $25.4bn
Q4 202212 holders, $831m35 holders, $27.6bn
Q1 202312 holders, $708m42 holders, $24.5bn
Q2 202312 holders, $703m38 holders, $25.0bn
Q3 202312 holders, $778m37 holders, $18.9bn
Q4 20237 holders, $754m31 holders, $19.0bn
Q1 20248 holders, $927m32 holders, $19.7bn
Q2 20247 holders, $823m35 holders, $20.4bn
Q3 20248 holders, $955m28 holders, $22.3bn
Q4 20247 holders, $801m37 holders, $20.4bn
Q1 20259 holders, $813m32 holders, $20.5bn
Q2 20259 holders, $642m31 holders, $18.4bn
Q3 202510 holders, $703m32 holders, $23.7bn
Q4 20259 holders, $566m29 holders, $27.8bn
Q1 202610 holders, $436m34 holders, $35.6bn
Q2 20269 holders, $1.2bn33 holders, $39.1bn
ALKS

Alkermes PLC

Holders
10
Reported value
$703m
Buyers
6
Sellers
4

Breadth +2 among 95 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
JNJ

Johnson & Johnson

Holders
32
Reported value
$23.7bn
Buyers
17
Sellers
13

Breadth +4 among 95 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q3 2025

Among the 37 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only ALKS (5)

Artisan Partners LP, ExodusPoint Capital Management LP, Farallon Capital Management LLC, Holocene Advisors LP, PDT Partners LLC

Only JNJ (27)

AllianceBernstein LP, AQR Capital Management LLC, Arrowstreet Capital LP, Balyasny Asset Management LLC, Brevan Howard Capital Management LP, Bridgewater Associates LP, Capital Research Global Investors, Caxton Associates LLP, Citadel Advisors LLC, D. E. Shaw & Co., Dodge & Cox, Fidelity (FMR LLC), Freestone Grove Partners LP, GAMCO Investors Inc, Invesco Ltd, Jane Street Group LLC, Janus Henderson Group Ltd, Markel Group Inc, Marshall Wace LLP, MFS Investment Management, Millennium Management LLC, Neuberger Berman Group LLC, Schonfeld Strategic Advisors LLC, Squarepoint Ops LLC, Two Sigma Advisers LP, and 2 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →